10月9日，拓新药业跌1.02%，成交额7372.32万元。两融数据显示，当日拓新药业获融资买入额820.85 万元，融资偿还1194.87万元，融资净买入-374.02万元。截至10月9日，拓新药业融资融券余额合计1.55 亿元。 融资方面，拓新药业当日融资买入820.85万元。当前融资余额1.55亿元，占流通市值的3.93%，融资余 额超过近一年70%分位水平，处于较高位。 资料显示，拓新药业集团股份有限公司位于河南省新乡市高新区科隆大道515号，成立日期2005年2月3 日，上市日期2021年10月27日，公司主营业务涉及化学合成、生物发酵核苷(酸)类原料药及医药中间体 的研发、生产及销售。主营业务收入构成为：医药中间体62.74%，原料药37.03%，其他(补充)0.23%。 截至9月19日，拓新药业股东户数1.65万，较上期减少26.77%；人均流通股5527股，较上期增加 36.55%。2025年1月-6月，拓新药业实现营业收入1.82亿元，同比减少16.85%；归母净利润-1828.05万 元，同比减少927.39%。 分红方面，拓新药业A股上市后累计派现9463.61万元。近三年，累计派现82 ...

Group 1 - On September 25, Toxin Pharmaceutical experienced a decline of 1.54% with a trading volume of 60.37 million yuan [1] - The financing data on the same day showed a financing purchase amount of 3.99 million yuan and a financing repayment of 7.89 million yuan, resulting in a net financing outflow of 3.89 million yuan [1] - As of September 25, the total balance of margin trading for Toxin Pharmaceutical was 157 million yuan, with a financing balance of 156 million yuan, accounting for 4.02% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - As of July 31, the number of shareholders for Toxin Pharmaceutical increased by 7.72% to 22,500, while the average circulating shares per person decreased by 7.16% to 4,048 shares [2] - For the first half of 2025, Toxin Pharmaceutical reported an operating income of 182 million yuan, a year-on-year decrease of 16.85%, and a net profit attributable to the parent company of -18.28 million yuan, a significant year-on-year decrease of 927.39% [2] - Since its A-share listing, Toxin Pharmaceutical has distributed a total of 94.64 million yuan in dividends, with 82.04 million yuan distributed over the past three years [2]

Group 1 - The article highlights the success of Tuoxin Pharmaceutical Group under the leadership of Chairman Yang Xining, emphasizing the company's journey from a technology-driven startup to a leading player in the pharmaceutical industry, culminating in its successful listing on the capital market [2] - Yang Xining's focus on core technologies, particularly in the field of nucleoside (acid) raw materials and pharmaceutical intermediates, has established Tuoxin Pharmaceutical as a leader in this high-barrier segment, with a comprehensive product chain covering various therapeutic areas [3] - The company has implemented international quality standards, achieving ISO9001 certification and GMP management for raw material production, which has facilitated its global market entry and product registration in countries like India and Uzbekistan [5] Group 2 - Under Yang Xining's leadership, Tuoxin Pharmaceutical has received multiple awards for its scientific contributions, including the "National Science and Technology Progress Award" and recognition as a "National High-tech Industry Demonstration Project," showcasing its research and industrial transformation capabilities [6] - Yang Xining actively engages in social responsibility and industry development, contributing to regional economic growth and fostering talent through academic collaborations and mentorship roles [8] - The successful listing of Tuoxin Pharmaceutical on the Shenzhen Stock Exchange in October 2021 marks a significant milestone, reflecting the company's robust development and setting the stage for future growth through capital market leverage [8]